Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Biogen Idec (BIIB - Analyst Report) recently announced the submission of a new drug application (NDA) for its oral multiple sclerosis candidate, BG-12. The NDA was based on data from the phase III DEFINE and CONFIRM studies which showed that treatment with BG-12 led to a significant reduction in disease activity in multiple sclerosis patients. Moreover, the candidate had a favorable safety and tolerability profile.

Biogen will be filing for EU approval as well shortly. A response regarding the acceptance of the NDA should be out in a couple of months. We believe BG-12 could become a leader in the oral multiple sclerosis market once launched.

In addition to announcing the submission of the BG-12 NDA, Biogen said that it gained US Food and Drug Administration (FDA) approval for Avonex Pen and a new dose titration regimen. The availability of Avonex Pen should help improve convenient administration of Avonex, which is approved for the treatment of relapsing forms of multiple sclerosis. Avonex Pen’s convenience of administration should improve patient independence and reduce injection anxiety.

Meanwhile, the new dose titration regimen, which increases the dose gradually, should help reduce the incidence and severity of flu-like symptoms which could occur at the commencement of treatment. Avonex Pen gained approval in the EU and Canada in 2011.

Neutral on Biogen

We currently have a Neutral recommendation on Biogen, which carries a Zacks #3 rank (short-term “Hold” rating). Key products, Avonex and Tysabri, should continue contributing significantly to sales. Longer-term growth could be driven by BG-12. However, we are concerned about Novartis’ (NVS - Snapshot Report) Gilenya which is competing directly with Avonex and Tysabri. The multiple sclerosis market could become more competitive with the entry of oral treatments being developed by Sanofi (SNY - Analyst Report).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%